Conditions: Postmenopausal Osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 923
Healthy volunteers: no

Brief summary:
The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

Detailed description:
The comparator arms of this risedronate study are 35 mg delayed release given weekly and 5 mg immediate release given daily.

Arms:
arm 1: 5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast) arm 2: 35 mg / Delayed-release Risedronate (Immediately Following Breakfast) arm 3: 35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)

Interventions: intervention 1: risedronate intervention 2: risedronate intervention 3: risedronate
Intervention descriptions: intervention 1: 5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily intervention 2: 35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly intervention 3: 35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly

Protocol document: